Source: Annual Congress 2012 - Novelties in clinical management of thoracic diseases: from diaphragm to pleura
Disease area: Respiratory infections, Thoracic oncology



Rating:

Share or cite this content

Citations should be made in the following way:
S. Ozsu, Y. Abul, A. Mentese, H. Bektas, A. Uzun, T. Ozlu (Trabzon, Turkey). Pentraxin-3: A novel biomarker for the differentiation of parapneumonic effusion and malignant pleural effusion. Eur Respir J 2012; 40: Suppl. 56, 1690

Member's Comments

No comment yet.

Related content which might interest you: Role of C-reactive protein in discriminating complicated and uncomplicated parapneumonic effusion from malignant and tuberculous pleural effusion Source: Virtual Congress 2021 – Clinical problems associated with cough, pleura and respiratory health status Year: 2021 Clinical role of pleural effusion MMP-3 levels in malignant pleural mesothelioma Source: Annual Congress 2012 - Biology and treatment of malignant pleural effusions Year: 2012 Procalcitonin in pleural fluid: A new tool for the diagnosis of empyema and parapneumonic pleural effusions? Source: Annual Congress 2011 - New aspects in prevention and treatment of community-acquired pneumonia and lower respiratory tract infections Year: 2011 Pleural fluid IL-6 levels in the identification of the complicated parapneumonic pleural effusion Source: Annual Congress 2008 - Pleural effusion Year: 2008 Transudative malignant pleural effusions Source: International Congress 2019 – Novel approaches to pleural effusion: should I change my practice? Year: 2019 Prognostic features of residual pleural thickening after parapneumonic pleural effusion Source: Eur Respir J 2002; 20: Suppl. 38, 605s Year: 2002 C-reactive protein in differentiation between tuberculous and malignant pleural effusions Source: Annual Congress 2011 - Clinical challenges in tuberculosis Year: 2011 Accuracy of pleural fluid c-reactive protein in differentiating between tuberculous and malignant pleural effusions: a meta-analysis Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019 Pleurodesis for malignant pleural effusion Source: School Course 2014 - Medical Thoracoscopy Year: 2014 Pleurodesis for malignant pleural effusion Source: ERS Course 2016 - Skills course on medical thoracoscopy Year: 2016 The value of IL6 in differentiation between malignant and non malignant pleural effusion Source: Annual Congress 2009 - Diagnosis of pleural effusions and rare tumours experience Year: 2009 Diagnostic approach in a patient with pleural effusion Source: ISSN=1025-448x, ISBN=1-904097-25-1, page=131 Year: 2002 Pleurodesis in the treatment of malignant pleural effusion Source: Eur Respir J 2004; 24: Suppl. 48, 628s Year: 2004 Separating malignant from nonmalignant pleural effusion on the basis of PO2 in pleural effusion Source: Eur Respir J 2003; 22: Suppl. 45, 541s Year: 2003 Loculated pleural effusion Source: ERS Skills Course 2018 - Thoracoscopy and pleural techniques Year: 2018 Is the size of pleural effusion important in the study of patients whose first tumor manifestation is a pleural effusion? Source: International Congress 2017 – Pleural and mediastinal malignancies Year: 2017 Management of malignant pleural effusion Source: Eur Respir J 2001; 18: Suppl. 33, 397s Year: 2001 Prognostic features of residual pleural thickening in parapneumonic pleural effusions Source: Eur Respir J 2003; 21: 952-955 Year: 2003 Value of pleural fluid and serum NT-ProBNP levels in differentiation of transudative and exudative pleural effusions Source: Annual Congress 2010 - Novel approach in diagnosis and treatment of pleural effusions Year: 2010